GlaxoSmithKline PLC ADR Market Cap ($111.15 Billion)
Market Cap & Net Worth: GlaxoSmithKline PLC ADR (GSK)
GlaxoSmithKline PLC ADR market cap. GlaxoSmithKline PLC ADR (NYSE:GSK) has a market capitalization of $111.15 Billion ($111.15 Billion) as of November 6, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #220 globally and #119 in its home market, demonstrating a -3.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlaxoSmithKline PLC ADR's stock price $55.63 by its total outstanding shares 1998088476 (2.00 Billion). Also see GlaxoSmithKline PLC ADR cash conversion from operations for how efficiently the company converts equity into cash flow.
GlaxoSmithKline PLC ADR Market Cap History (2015–2026)
GlaxoSmithKline PLC ADR market cap history from 2015 to 2026. Data shows growth from $52.59 Billion to $102.20 Billion (7.17% CAGR). Check GlaxoSmithKline PLC ADR share price for real-time trading data and today's change.
Index Memberships
GlaxoSmithKline PLC ADR is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.46 Trillion | 3.22% | #9 of 24 |
Weight: GlaxoSmithKline PLC ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
GlaxoSmithKline PLC ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlaxoSmithKline PLC ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore GlaxoSmithKline PLC ADR (GSK) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.00x
GlaxoSmithKline PLC ADR's market cap is 3.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
17.14x
GlaxoSmithKline PLC ADR's market cap is 17.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $53.63 Billion | $27.89 Billion | $912.00 Million | 1.92x | 58.80x |
| 2017 | $51.98 Billion | $30.19 Billion | $1.53 Billion | 1.72x | 33.93x |
| 2018 | $59.09 Billion | $30.82 Billion | $3.62 Billion | 1.92x | 16.31x |
| 2019 | $76.30 Billion | $33.75 Billion | $4.64 Billion | 2.26x | 16.43x |
| 2020 | $62.74 Billion | $24.35 Billion | $5.75 Billion | 2.58x | 10.91x |
| 2021 | $79.45 Billion | $24.70 Billion | $4.38 Billion | 3.22x | 18.12x |
| 2022 | $64.93 Billion | $29.32 Billion | $14.96 Billion | 2.21x | 4.34x |
| 2023 | $71.24 Billion | $30.33 Billion | $4.93 Billion | 2.35x | 14.46x |
| 2024 | $67.58 Billion | $31.38 Billion | $2.58 Billion | 2.15x | 26.24x |
| 2025 | $97.99 Billion | $32.67 Billion | $5.72 Billion | 3.00x | 17.14x |
Competitor Companies of GSK by Market Capitalization
Companies near GlaxoSmithKline PLC ADR in the global market cap rankings as of November 6, 2026. Also see GlaxoSmithKline PLC ADR total assets for a full breakdown of the balance sheet.
Key companies related to GlaxoSmithKline PLC ADR by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1417.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $276.32 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $294.83 |
Market Capitalization of GlaxoSmithKline PLC ADR (2015–2026)
Market capitalization of GlaxoSmithKline PLC ADR from 2015 to today. Between 2015 and today, GlaxoSmithKline PLC ADR's market cap moved from $52.59 Billion to $ 102.20 Billion, with a yearly change of 7.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $102.20 Billion | +4.30% |
| 2025 | $97.99 Billion | +45.00% |
| 2024 | $67.58 Billion | -5.14% |
| 2023 | $71.24 Billion | +9.71% |
| 2022 | $64.93 Billion | -18.27% |
| 2021 | $79.45 Billion | +26.63% |
| 2020 | $62.74 Billion | -17.78% |
| 2019 | $76.30 Billion | +29.12% |
| 2018 | $59.09 Billion | +13.68% |
| 2017 | $51.98 Billion | -3.07% |
| 2016 | $53.63 Billion | +1.97% |
| 2015 | $52.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of GlaxoSmithKline PLC ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $111.15 Billion USD |
| MoneyControl | $111.15 Billion USD |
| MarketWatch | $111.15 Billion USD |
| marketcap.company | $111.15 Billion USD |
| Reuters | $111.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GlaxoSmithKline PLC ADR
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more